Immunexpress Inc.

Immunexpress Inc. is a biotechnology startup with a mission to revolutionize sepsis diagnosis with their flagship product, SeptiCyte®. Founded in 2006, the company is headquartered in Seattle, USA and has an office in Brisbane, Australia. Immunexpress's pioneering technology analyzes the immune system to swiftly detect sepsis, addressing critical unmet clinical needs for patients and healthcare systems. Unlike traditional approaches, SeptiCyte® quantifies specific molecular biomarkers from a patient's immune system, offering the potential for early sepsis detection and guiding treatment strategies. Their last investment was a Venture - Series Unknown round on 03 October 2019, indicating ongoing support and interest in their innovative approach.